Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for the sweet spot in chemo dosing

NCT ID NCT00145028

Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 23, 2026 · Updated 1 time

Summary

Researchers want to find the best dose of carboplatin, a chemotherapy drug, by measuring how much of it stays in the blood. They will study 400 adults with cancer who are receiving carboplatin. The goal is to figure out the ideal drug exposure and what factors affect it, so doctors can standardize dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carboplatin, a chemotherapy drug
What this could lead to
If successful, this could lead to more personalized carboplatin dosing, helping doctors give the right amount for each patient to improve safety and effectiveness.
What could go wrong
This is an observational study, not a randomized trial, so it may not prove that personalized dosing improves outcomes. Finding the optimal dose for each patient is complex and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Start date

May 2005

Finished

Feb 2009

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Carcinoma histologically proved and which must be treated by Carboplatin, excepted weekly administered Carboplatin treatments * Age \> 18 years * Neutrophils \> 1500/mm3, blood-platelets \> 100000/mm3 * Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination) * Well-informed written consent, signed by the patient Exclusion Criteria: * Carboplatin treatment's contra-indication * Patient with clinically detectable cerebral metastasis * Pregnant or nursing women * Patient under guardianship or trusteeship * Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoplasms

Contacts and locations

Locations

  • CHRU Bretonneau

    Tours, France

  • CHU A. Michallon

    Grenoble, France

  • CHU de Nîmes

    Nîmes, France

  • CHU de Toulouse Rangueil

    Toulouse, France

  • CHU de la Timone

    Marseille, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre Oscar Lambert

    Lille, France

  • Centre Paul Papin

    Angers, France

  • Centre René Gauducheau

    Saint Herblain (Nantes), France

  • Centre Val d'Aurelle

    Montpellier, France

  • Clinique Mathilde

    Rouen, France

  • Clinique Pasteur

    Évreux, France

  • Hopital Européen Georges Pompidou

    Paris, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Claudius Regaud

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.